GALT Galectin Therapeutics Inc

Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that Harold, Shlevin, Ph.D, chief operating officer, will present a corporate overview and update at the 27th Annual ROTH Conference on March 9, 2015 at 11:00 a.m. Pacific time. The conference is being held at the Ritz Carlton, Laguna Niguel in Dana Point, Calif. from March 8 through March 11.

To listen to the presentation, investors may visit the investor relations section of Galectin Therapeutics' website at www.galectintherapeutics.com. An archived audio of the presentation will also be available on Galectin Therapeutics' website for 90 days.

About Galectin Therapeutics

Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.

CONTACT: Galectin Therapeutics Inc.
         Peter G. Traber, M.D.
         President, CEO & CMO
         (678) 620-3186
         ir@galectintherapeutics.com
         
         LHA
         Kim Golodetz
         (212) 838-3777
         kgolodetz@lhai.com